ORGO — Organogenesis Holdings Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1661181 ·
Last close
$0.81
Market Cap
$105.35M
52W High
$5.99
52W Low
$0.73
ADV30
1,039,985
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 45,457,000 | 23,559,000 | -29,489,000 | -29,629,000 | 368,905,000 | 21,326,000 | 106,164,000 |
| Jun 2026 | 42,805,000 | 19,132,000 | -52,180,000 | -96,267,000 | 406,446,000 | 46,097,000 | 118,314,000 |
| Mar 2026 | 36,250,000 | 10,478,000 | -68,891,000 | -53,156,000 | 519,992,000 | 91,379,000 | 138,645,000 |
| Dec 2025 | 225,071,000 | 175,153,000 | 65,229,000 | 43,700,000 | 598,730,000 | 93,679,000 | 164,812,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$31,973,000
Investing CF
$-11,133,000
Financing CF
$-47,731,000
CapEx
$-11,133,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.86
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-152,501,000
Inventory
$29,280,000
Receivables
$100,937,000
ST Investments
—
EBIT TTM
$-34,193,000
Pretax Income TTM
$-34,766,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$352,047,008
EBITDA
$-56,943,000
Free Cash Flow
$24,084,250
Enterprise Value
$291,748,768
Total Cash
$21,326,000
Total Debt
$64,516,000
Shares Out
129,801,720
Trailing EPS
$-1.20
Book Value
$0.92
ROE
-41.7%
ROA
-11.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 563,030,000 | 55,869,000 | 37,032,000 | 598,730,000 | 164,812,000 | 433,918,000 | -10,309,000 |
| Dec 2024 | 482,043,000 | 21,518,000 | 861,000 | 497,886,000 | 112,570,000 | 385,316,000 | 14,208,000 |
| Dec 2023 | 433,140,000 | 12,525,000 | 4,945,000 | 460,025,000 | 181,362,000 | 278,663,000 | 30,917,000 |
| Dec 2022 | 450,893,000 | 22,304,000 | 15,532,000 | 449,359,000 | 183,690,000 | 265,669,000 | 24,859,000 |
TTM Snapshot
Revenues TTM
$457,454,000
NetIncome TTM
$-84,156,000
OpCashFlow TTM
—
Assets (Latest)
$406,446,000
Forward EPS
$-0.31
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NRXP | NRX Pharmaceuticals, Inc. | $106.07M | $2.45 | — |
| OKUR | OnKure Therapeutics, Inc. | $104.50M | $2.58 | — |
| CATX | Perspective Therapeutics, Inc. | $103.84M | $0.86 | — |
| NERV | Minerva Neurosciences, Inc. | $103.13M | $2.16 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $101.90M | $0.71 | — |
News headlines (Yahoo Finance, 1h cache)
Organogenesis Holdings Inc (ORGO) Q3 2026 Earnings Call Highlights: Market Bottom, Cost Cuts, ...
2026-11-07 15:09 · Yahoo
Organogenesis Holdings Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Organogenesis: 3 Key Takeaways for Long-Term Investors
2026-11-06 11:45 · Yahoo
Organogenesis (ORGO) Q3 2026 Earnings Call Transcript
2026-11-06 09:30 · Yahoo
Organogenesis: Q3 Earnings Snapshot
2026-11-05 22:05 · Yahoo
Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
2026-11-05 21:05 · Yahoo
Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
2026-10-12 20:10 · Yahoo
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
2026-10-12 20:05 · Yahoo
Organogenesis (ORGO) Q2 2026 Earnings Call Transcript
2026-08-13 23:46 · Yahoo
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
2026-07-09 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.